Tetracyclines
Staphylococcus aureus, Streptococcus pneumonia, Streptococcus pyogenes, Streptooccus agalacticae, Campylobacter jejuni, Haemophilus influenzae, Neisseria gonorrhoeae, Neisseria meningitides,Clostridium spp., Peptostreptococcus spp., Peptococcus spp. Bacteroides melaninogenicus, Bacteroides fragilis
Inhibits bacterial protein synthesis by binding with the 30S ribosomal subunit.
Tetracyclines produce a combination of concentration and time-dependent killing (AUC:MIC ratio).
Dose of 200mg PO: Cmax: 2-3.5 mcg/mL; Tmax: 1-4 hours; Half-life: 11-26 hours; Volume of distribution: 60 L/kg; Table 3
GI: epigastric burning, abdominal discomfort, nausea, vomiting, anorexia, diarrhea, esophagitis, esophageal ulcers, dysphagia, candidal superinfections
Teeth and bone: (dose/duration related) yellow discoloration of teeth, which turns into a gray-brown permanent discoloration, hypoplasia of enamel, teeth demineralization, skeletal growth retardation
Hepatotoxicity: rare, but fatal; intrahepatic cholestasis, jaundice, azotemia, acidosis, irreversible shock
Renal Toxicity: hyperphosphatemia, acidosis, polyuria, polydipsia
Photosensitivity and hyperpigmentation: red rash to blistering on sun-exposed areas; photoallergic reactions manifested by paresthesias of hands, feet, nose, photo-onycholysis
Auditory: tinnitus, hearing loss
Vision: visual disturbances
CNS: lightheadedness, dizziness, ataxia, drowsiness, headache
Oral: 50mg, 75mg, 100mg capsules
50mg/5mL suspension
50mg, 75mg, 100mg tablets
Acne vulgaris: 200 mg IV or PO x 1, then 100 mg IV or PO q12h
Bartonellosis: 200 mg IV or PO x 1, then 100 mg IV or PO q12h
Brucellosis: 200 mg IV or PO x 1, then 100 mg IV or PO q12h
Chlamydial infection: 100 mg PO q12h x minimum 7 days
Cholera: 200 mg IV or PO x 1, then 100 mg IV or PO q12h
Rickettsial disease: 200 mg IV or PO x 1, then 100 mg IV or PO q12h
Psittacosis: 200 mg IV or PO x 1, then 100 mg IV or PO q12h
2-4 mg/kg divided q12h
Renal failure: No dosing change necessary
Hepatic failure: No dosing changes recommended at this time.
Precautions: Usage in newborns, infants, and children less than 8 years of age; risk for tooth discoloration; Renal or liver impairment; Phototoxicity; Avoid in patients with systemic lupus erythematosus (SLE);
Food: Decreased absorption of minocycline
Milk: Decreased absorption of minocycline
Oral contraceptives: Decreased contraceptive effectiveness
Warfarin: Increased warfarin effect
Category D: Risk established, but benefits may outweigh risk.
Therapeutic: Culture and sensitivities, serum levels, signs and symptoms of infection, white blood cell count
Toxic: Hypersensitivity syndrome reaction, serum sickness like reaction or single organ dysfunction – Monitor: CBC, LFTs, urinalysis, urea, creatinine, chest radiograph; Drug-induced lupus: monitor antinuclear antibody and hepatic transaminases; General long-term therapy: Liver and renal function tests, Hematopoietic studies
DynacinÒ/Medicis; MinocinÒ/Lederle; MinocyclineÒ/Generva; VectrinÒ/Warner Chilcott